

**Emerging Targets in Gastrointestinal Cancers:  
Established Biomarkers – Why and How We Test**

**Clinical Brief Tweeterial #2**

**References**

Catenacci DVT, Kang Y-K, Saeed A, et al. FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bema combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). *J Clin Oncol*. 2021;39(15\_suppl):4010-4010. doi:10.1200/JCO.2021.39.15\_suppl.4010

ClinicalTrials.gov. A study of zolbetuximab (IMAB362) plus CAPOX compared with placebo plus CAPOX as first-line treatment of subjects with claudin (CLDN) 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (GLOW). NCT03653507. Updated March 17, 2022. Accessed March 31, 2022. <https://clinicaltrials.gov/ct2/show/NCT03653507>

ClinicalTrials.gov. A study of bema combined with modified FOLFOX6 (mFOLFOX6) in gastric/gastroesophageal junction cancer (FIGHT) (FIGHT). NCT03694522. Updated May 3, 2021. Accessed March 31, 2022. <https://clinicaltrials.gov/ct2/show/NCT03694522>

Janjigian YY, Kawazoe A, Yanez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. *Nature*. 2021;600(7890):727-730. doi:10.1038/s41586-021-04161-3

JEMPERLI (dostarlimab-gxly) [prescribing information]. GlaxoSmithKline. Approved 2021. Revised April 2022. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/761174s002lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761174s002lbl.pdf)

KEYTRUDA® (pembrolizumab) [prescribing information]. Merck Sharp & Dohme Corp. Approved 2014. Revised March 2022. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/125514s110lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s110lbl.pdf)

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Esophageal and Esophagogastric Cancers (v2.2022). Updated February 11, 2022. Accessed March 30, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/esophageal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf)

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Gastric Cancer (v2.2022). Updated January 11, 2021. Accessed March 30, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/gastric.pdf](https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf)

OPDIVO (nivolumab) [prescribing information]. Bristol-Myers Squibb. Approved 2014. Revised March 2022. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/125554s112lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s112lbl.pdf)

ROZLYTREK (entrectinib) [prescribing information]. Genentech. Approved 2019. Revised November 2021. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/212725s005lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212725s005lbl.pdf)

Shitara K, Seraj J, Franke FA, et al. 1436TiP Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized phase III study. *Ann Oncol.* 2021;32:S1073. doi:10.1016/j.annonc.2021.08.1545

VITRAKVI® (larotrectinib) [prescribing information]. Bayer HealthCare Pharmaceuticals Inc. Approved 2018. Revised March 2021.

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/210861s006lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210861s006lbl.pdf)

Wainberg ZA, Enzinger PC, Kang Y-K, et al. Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT). *J Clin Oncol.* 2021;39(3\_suppl):160-160. doi:10.1200/JCO.2021.39.3\_suppl.160

---

## Glossary

1L, first line  
2L, second line  
3L, third line  
AE, adverse event  
ALT, alanine aminotransferase  
AST, aspartate aminotransferase  
Chemo, chemotherapy  
CI, confidence interval  
CLDN18.2, claudin-18 isoform 2  
CPS, Combined Positive Score  
FGFR2b, fibroblast growth factor receptor 2 isoform IIIb  
FISH, fluorescence in situ hybridization  
G, gastric  
GC, gastric cancer  
GEJ, gastroesophageal  
GI, gastrointestinal  
HER2, human epidermal growth factor receptor 2  
HR, hazard ratio  
IHC, immunohistochemistry  
IO, immuno-oncology  
ISH, in situ hybridization  
mDOR, median duration of response  
mFOLFOX6, levofolonic acid, 5-FU, and oxaliplatin for 6 cycles  
MMR, mismatch repair  
mOS, median overall survival

mPFS, median progression-free survival  
MSI, microsatellite instability  
NCCN, National Comprehensive Cancer Network  
NGS, next-generation sequencing  
NTRK, neurotrophic tyrosine receptor kinase  
ORR, objective response rate  
OS, overall survival  
PCR, polymerase chain reaction  
PD-1, programmed cell death protein 1  
Pembro, pembrolizumab  
PD-L1, programmed death-ligand 1  
PFS, progression-free survival  
T-DXd, trastuzumab deruxtecan  
TRAE, treatment-related adverse event  
TRK, tyrosine receptor kinase  
w/, with